American Renal Associates Stock Forecast, Price & News

Wall Street analysts have given American Renal Associates a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but American Renal Associates wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

American Renal Associates Holdings, Inc. (NYSE:ARA) issued its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.09. The business had revenue of $209.69 million for the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%.
View American Renal Associates' earnings history.

62 employees have rated American Renal Associates CEO Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among American Renal Associates' employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to American Renal Associates include Tivity Health (TVTY), Convey Holding Parent (CNVY), Ontrak (OTRK), SOC Telemed (TLMD), HemaCare (HEMA), Viemed Healthcare (VMD), Viemed Healthcare (VMD), Greenbrook TMS (GBNH), Caladrius Biosciences (CLBS), Cryo-Cell International (CCEL), Curative Biotechnology (CUBT), Baudax Bio (BXRX), Curative Biotechnology (CTYX), BioRestorative Therapies (BRTX) and Pacific Health Care Organization (PFHOD).
View all of ARA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include KemPharm (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).

(ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

One share of ARA stock can currently be purchased for approximately $11.52.

American Renal Associates has a market capitalization of $397.94 million and generates $822.52 million in revenue each year. The company earns $-13,790,000.00 in net income (profit) each year or $0.26 on an earnings per share basis.

American Renal Associates employs 4,977 workers across the globe.

The official website for American Renal Associates is www.americanrenal.com.

American Renal Associates is headquartered at 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915.

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]